Download
fair hf n.
Skip this Video
Loading SlideShow in 5 Seconds..
FAIR-HF PowerPoint Presentation

FAIR-HF

344 Vues Download Presentation
Télécharger la présentation

FAIR-HF

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. FAIR-HF Primary outcome, Patient Global Assessment at 24 weeks: Much or moderately improved in 50% of the intravenous iron group vs. 28% of the placebo group (p < 0.001) New York Heart Association (NYHA) class I or II at 24 weeks: 47% vs. 30% (p < 0.001) Death: 3.4% vs. 5.5% (p = 0.47) Hospitalization for any cardiovascular cause: 10.4% vs. 20.0% (p = 0.08) Trial design: Patients with chronic heart failure and iron deficiency (with or without anemia) were randomized to intravenous iron (ferric carboxymaltose) (n = 304) vs. placebo (n = 155) for 24 weeks. Results (p < 0.001) (p < 0.001) % Conclusions • Among patients with chronic heart failure and iron deficiency, the use of intravenous iron for 24 weeks was beneficial • This therapy resulted in improved symptoms and functional capacity • Intravenous iron appeared to be safe Much or moderately improved patient assessment NYHA class I or II Intravenous iron Placebo Anker SD, et al. N Engl J Med 2009;Nov 17:[Epub]